BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
토요일, 9월 19

Cabaletta Bio Inc

CABANASDAQ
Trade with Public
Trade with Public
$2.55
-0.03-1.16%
가까이에: Sep 18, 5:00 PM EST
$2.64
0.08743.43%
시간외: 7:41 PM EST
개요뉴스실적 전망이벤트재무심리지분 현황비교옵션주식 보고서

Cabaletta Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cabaletta Bio (CABA).

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

8Buy
1Hold
Consensus RatingBuy# Analysts9Avg. Consensus PT$20Upside to Avg. PT+654.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 1, 2026HC Wainwright & Co.Douglas TsaoMaintainedBuy$16
Aug 14, 2026Wells FargoDerek ArchilaPT CutEqual-Weight$4→$3
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $16 price target.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and raises the price target from $2 to $4.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target

Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $30 price target.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13

Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $14 to $13.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16

Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $15 to $16.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved